Loading
A phase 1/2 trial of Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib and Everolimus in HR-positive / HER2-negative breast cancer, run by Hoffmann-La Roche, now recruiting.
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer is a phase 1/2 interventional study registered as NCT04802759 by Hoffmann-La Roche, with 316 participants planned, started 2021-06-22 and due to reach its primary completion in 2029-05-30. Interventions recorded: Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib and Everolimus.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Giredestrant, Flatiron Health (Roche), Ribociclib, Abemaciclib and the tag pipeline.
Shares Giredestrant, Inavolisib, Flatiron Health (Roche), Ribociclib and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche), Abemaciclib, UCSF Helen Diller Family Comprehensive Cancer Center and the tag pipeline.
Shares Ribociclib, Abemaciclib, UCSF Helen Diller Family Comprehensive Cancer Center, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Inavolisib, Flatiron Health (Roche), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Inavolisib, Flatiron Health (Roche), Ribociclib and the tag pipeline.
Shares Ribociclib, Abemaciclib, Everolimus and the tag pipeline.
Shares Giredestrant, Flatiron Health (Roche) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/